Type 2 Diabetes Mellitus
Conditions
Brief summary
To assess the safety and effectiveness of two doses of SugarDown in two different doses vs. placebo on serum glucose levels after meals in subjects with Type 2 Diabetes treated with metformin alone. There will be five visits, a screening visit, baseline visit, and 3 treatment visits. The study duration will be five weeks. Subjects will all receive placebo tablets at the baseline visit, eat a standard rice meal, and then serum glucose levels will be measured in frequent intervals over four hours immediately following the meal. Subjects will be randomized to one of the six treatment sequences. Patients will take in an unknown order one week of placebo, one week of 4 g dose and one week of 8 g dose of SugarDown immediately before breakfast, lunch and dinner meals. Patients will continue their usual metformin regimen during the trial period.
Interventions
DIETARY_SUPPLEMENTSugarDown
4 or 8 gram dose in tablet form, before meals, daily for one week
DRUGPlacebo Oral Tablet
Placebo comparator
Sponsors
Boston Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
25 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent prior to any trial-related activity * Male or female, between 25-75 years of age * A diagnosis of Type 2 Diabetes for at least one year prior to screening visit * Stable daily dose of metformin (up to 1.7 g daily) for at least 3 months prior to screening visit * Body Mass Index (BMI) between 25 and 35 * HbA1c between 6.5% and 9.0% * Fasting blood glucose \< 180 mg/dL
Exclusion criteria
* Clinically significant cardiovascular, peripheral vascular, cerebrovascular or renal disease * Any clinical condition apart from diabetes Type 2 that affects glycemic control, examples include diabetes Type 1, liver disease, chronic pancreatitis, endocrine disease (e.g. pituitary, thyroid, adrenal gland disease), small or large intestine motility or absorptive disease, active infection, advanced malignant tumor or bariatric surgery * Any concomitant anti-diabetic medication other than metformin, including, but not limited to, the following classes of medication: insulin, sulfonylureas, glinides, glitazones, alpha-glucosidase inhibitors, amylin agonists, DPP-4 inhibitors, and GLP-1 agonists * Any concomitant steroid, hormonal, anorexic or other medications that could significantly interfere with glycemic control in subjects * Lactating or pregnant women, or women of child-bearing potential unable to use adequate birth control. * History or patient reported illicit drug abuse or alcoholism * Participation in another clinical study one month preceding recruitment * Any of the following laboratory abnormalities: AST or ALT \> 1.5 times upper limit normal on liver function test, glomerular filtration rate \< 60 (mL/min/1.73 m2) on chemistry panel measured by MDRD criteria, and hemoglobin \< 10 g/dL on complete blood count
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postprandial serum glucose area under the curve in mg*hr/dL over four hours | One week |
Secondary
| Measure | Time frame |
|---|---|
| Peak postprandial serum glucose in mg/dL | One week |
| Time to peak postprandial serum glucose in minutes | One week |
| Peak blood serum excursion at 2 hours from baseline in mg/dL | One week |
Countries
United States
Outcome results
None listed